Acknowlegements

The authors thank Carol Pearce for her editing assistance.

References

[1] DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 7th edition. Philadelphia: Williams and Wilkins; 2005.

[2] Cheng E, Cvitkovic E, Wittes RE, et al. Germ cell tumors (II): VAB II in metastatic testicular cancer. Cancer 1978;42:2162-8.

[3] Einhorn LH, Donohue J. Cis-diamminedichloropla-tinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977;87:293-8.

[4] Reynolds TF, Vugrin D, Cvitkovic E, et al. VAB-3 combination chemotherapy of metastatic testicular cancer. Cancer 1981;48:888-98.

[5] Vugrin D, Whitmore WF, Cvitkovic E, et al. Adjuvant chemotherapy combination of vinblastine, acti-nomycin D, Bleomycin, and Chlorambucil following retroperitoneal lymph node dissection for stage II testis tumor. Cancer 1981;47:840-4.

[6] Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus eto-poside and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. J Clin Oncol 1993;11:598-606.

[7] Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dacti-nomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 1988;6:1231-8.

[8] Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7:387-91.

[9] Loehrer PJ Sr, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13: 470-6.

[10] Xiao H, Mazumdar M, Bajorin DF, et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 1997;15:2553-8.

[11] Donohue JP, Einhorn LH, Perez JM. Improved management of nonseminomatous testis tumors. Cancer 1978;42:2903-8.

[12] Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroper-itoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005;23: 2781-8.

[13] Foster RS, Roth BJ. Clinical stage I nonseminoma: surgery versus surveillance. Semin Oncol 1998;25: 145-53.

[14] Johnson DE, Bracken RB, Blight EM. Prognosis for pathologic stage I non-seminomatous germ cell tumors of the testis managed by retroperitoneal lym-phadenectomy. J Urol 1976;116:63-5.

[15] Bredael JJ, Vugrin D, Whitmore WF Jr. Selected experience with surgery and combination chemotherapy in the treatment of nonseminomatous testis tumors. J Urol 1983;129:985-8.

[16] Jacobs EM, Muggia FM. Testicular cancer: risk factors and the role of adjuvant chemotherapy. Cancer 1980;45:1782-90.

[17] Vogelzang NJ, Fraley EE, Lange PH, et al. Stage II nonseminomatous testicular cancer: a 10-year experience. J Clin Oncol 1983;1:171-8.

[18] Vugrin D, Whitmore W, Cvitkovic E, et al. Adjuvant chemotherapy with VAB-3 of stage II-B testicular cancer. Cancer 1981;48:233-7.

[19] Vugrin D, Cvitkovic E, Whitmore WF Jr, et al. VAB-4 combination chemotherapy in the treatment of metastatic testis tumors. Cancer 1981;47:833-9.

[20] Vugrin D, Whitmore WF Jr, Herr HW, et al. VAB-6 combination chemotherapy in resected stage II-B testis cancer. Cancer 1983;51:5-8.

[21] Weissbach L, Hartlapp JH. Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol 1991;146:1295-8.

[22] Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 1991;9:1393-6.

[23] Skinner DG, Scardino PT. Relevance of biochemical tumor markers and lymphadenectomy in management of non-seminomatous testis tumors: current perspective. J Urol 1980;123:378-82.

[24] Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II tes-ticular cancer. N Engl J Med 1987;317:1433-8.

[25] Vugrin D, Whitmore WF Jr, Herr H, et al. Adjuvant vinblastine, actinomycin D, bleomycin, cyclophos-phamide and cis-platinum chemotherapy regimen with and without maintenance in patients with resected stage IIB testis cancer. J Urol 1982;128:715-7.

[26] Hartlapp JH, Weissbach L, Bussar-Maatz R. Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl 1987;10:277-84.

[27] Pizzocaro G, Monfardini S. No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. J Urol 1984;131:677-80.

[28] Fraley EE, Narayan P, Vogelzang NJ, et al. Surgical treatment of patients with stages I and II nonsemi-nomatous testicular cancer. J Urol 1985;134:70-3.

[29] Bajorin DF, Geller NL, Weisen SF, et al. Two-drug therapy in patients with metastatic germ cell tumors. Cancer 1991;67:28-32.

[30] Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-40.

[31] Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etopo-side and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 1995;13:2700-4.

[32] Pizzocaro G, Piva L, Salvioni R, et al. Adjuvant chemotherapy in resected stage-II nonseminomatous germ cell tumors of testis. In which cases is it necessary? Eur Urol 1984;10:151-8.

[33] Kondagunta GV, Sheinfeld J, Mazumdar M, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004;22(3): 464-7.

[34] Kondagunta GV, Bacik J, Bajorin D, et al. Etopo-side and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005; 23(36):9290-4.

[35] Behnia M, Foster R, Einhorn LH, et al. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: the Indiana University experience. Eur J Cancer 2000; 36:472-5.

[36] Rabbani F, Sheinfeld J, Farivar-Mohseni H, et al. Low-volume nodal metastases detected at retroperi-toneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 2001;19:2020-5.

Urol Clin N Am 34 (2007) 187-197

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment